In This Section      
 

Search Results

Title:
A Pilot Study of Stereotactic Radiosurgery combined with Nivolumab in Patients with Newly Diagnosed Melanoma Metastases in the Brain and Spine
Protocol Number:
J15214
Phase:
Phase I
Physician:
Michael Lim
Sites:
Johns Hopkins Kimmel Cancer Center in Baltimore
Purpose:
This research is being done to look at the safety of using stereotactic radiosurgery (SRS) and Nivolumab together to treat melanoma that has spread to the brain or spine.
Eligibility:
People at least 18 years old with melanoma that has newly spread to the brain or spine may be able to join. Participants must have adequate lab values and be able and willing to follow study requirements.
Treatment:
You will receive standard of care nivolumab every 2 weeks. Nivolumab is administered by IV infusion, meaning the drug is given through a vein. The nivolumab infusion usually takes about 1 hour (60 minutes). An intravenous infusion pump will be used to ensure the correct amount of study drug is given over the proper amount of time. You will receive SRS to treat your brain or spine metastasis per standard of care about 7 days following the first dose of nivolumab. ks after SRS per standard of care.
Population:
Adult
Last Update
03/05/2019 05:03 AM